ADPT

Adaptive Biotechnologies Corp

Sep 17 • 03:53PM ET

12.80

-0.11 -0.85 %

Healthcare • Biotechnology • USA • NASD

Peers: ILMN TXG GH PACB QGEN TWST FATE BEAM CRSP VRTX

| Held by: VTI IWM ARKG VB IWO VXF VBK IBB VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-0.81	Insider Own	4.61%	Shs Outstand	152.23M	Perf Week	3.06%
Market Cap	1.95B	Forward P/E	-	EPS next Y	-0.59	Insider Trans	-1.52%	Shs Float	145.25M	Perf Month	3.14%
Enterprise Value	1.97B	PEG	-	EPS next Q	-0.18	Inst Own	95.06%	Short Float	5.80%	Perf Quarter	26.23%
Income	-121.23M	P/S	9.50	EPS this Y	32.78%	Inst Trans	-2.30%	Short Ratio	3.95	Perf Half Y	74.15%
Sales	205.22M	P/B	10.84	EPS next Y	18.57%	ROA	-22.42%	Short Interest	8.43M	Perf YTD	113.51%
Book/sh	1.18	P/C	9.85	EPS next 5Y	32.06%	ROE	-57.55%	52W High	13.68 -6.43%	Perf Year	177.66%
Cash/sh	1.30	P/FCF	-	EPS past 3/5Y	9.79% -1.51%	ROIC	-31.52%	52W Low	3.98 221.53%	Perf 3Y	41.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	5.06% 16.04%	Gross Margin	60.69%	Volatility	6.56% 4.88%	Perf 5Y	-67.32%
Dividend TTM	-	EV/Sales	9.59	EPS Y/Y TTM	44.48%	Oper. Margin	-58.88%	ATR (14)	0.66	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.75	Sales Y/Y TTM	21.60%	Profit Margin	-59.07%	RSI (14)	52.52	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	2.84	EPS Q/Q	46.30%	SMA20	-0.34%	Beta	2.05	Target Price	14.00
Payout	-	Debt/Eq	1.21	Sales Q/Q	36.33%	SMA50	6.79%	Rel Volume	0.56	Prev Close	12.91
Employees	619	LT Debt/Eq	1.14	Earnings	Aug 05 AMC	SMA200	40.22%	Avg Volume	2.13M	Price	12.80
IPO	Jun 27, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	28.81% 19.20%	Trades		Volume	1,165,014	Change	-0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-25	Initiated	Craig Hallum	Buy	$15
Mar-21-25	Upgrade	Goldman	Neutral → Buy	$9
Jul-05-23	Resumed	JP Morgan	Overweight	$15
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$15
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight	$7.50 → $14
Aug-25-22	Initiated	Credit Suisse	Underperform	$8
Jun-03-22	Initiated	Piper Sandler	Neutral	$7.50
Feb-16-22	Reiterated	JP Morgan	Overweight	$75 → $50
Feb-16-22	Reiterated	Goldman	Neutral	$54 → $21
Feb-16-22	Reiterated	BTIG Research	Buy	$35 → $30
Feb-16-22	Reiterated	BofA Securities	Buy	$40 → $32
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral	$74 → $63
Oct-08-20	Resumed	BTIG Research	Buy	$60
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight	$42
Jun-03-20	Initiated	Goldman	Buy	$60
Jul-23-19	Initiated	BTIG Research	Buy	$46
Jul-22-19	Initiated	William Blair	Outperform
Jul-22-19	Initiated	Guggenheim	Buy	$47
Jul-22-19	Initiated	Goldman	Neutral	$32

Show Previous Ratings

Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-11-25 11:57AM	FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer (Zacks) +8.62%
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
09:40AM	Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks)
10:04AM	Loading…
10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Sep-04-25 10:48AM	SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study (Zacks)
Sep-01-25 12:30PM	Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice (Zacks)
Aug-29-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-27-25 04:05PM	Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-25-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
12:08AM	Adaptive Biotechnologies (ADPT) Poised for $33.7M Windfall on Genentech Deal Termination (Insider Monkey)
Aug-19-25 07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive)
Aug-13-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? (Zacks)
09:40AM	Loading…
Aug-08-25 09:40AM	Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-06-25 07:01PM	Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday (Motley Fool) +5.79% +7.27%
03:30AM	Adaptive Biotechnologies Corp (ADPT) Q2 2025 Earnings Call Highlights: Strong MRD Growth and ... (GuruFocus.com)
Aug-05-25 07:30PM	Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings (Zacks)
06:00PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:57PM	Adaptive Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:38AM	Adaptive Biotechnologies Corp (ADPT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.61%
Aug-01-25 08:10AM	Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-22-25 08:14AM	Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results (Insider Monkey)
Jul-15-25 04:05PM	Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 (GlobeNewswire)
Jul-04-25 09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
Jul-01-25 07:30AM	Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ MRD Testing into OncoEMR (GlobeNewswire)
Jun-26-25 09:49AM	Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains? (Zacks)
Jun-25-25 01:01PM	Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy (Insider Monkey) +12.49%
12:00PM	Loading…
Jun-13-25 12:00PM	What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock (Zacks)
Jun-11-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-03-25 04:05PM	Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors (Business Wire)
May-30-25 07:30AM	Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers (GlobeNewswire)
May-29-25 11:18AM	SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal (Zacks)
11:08AM	U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot (Zacks)
06:20AM	Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? (Zacks)
May-28-25 04:05PM	Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-26-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
May-20-25 06:20AM	Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar? (Zacks)
May-19-25 09:06AM	BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz (Zacks)
May-15-25 08:42AM	AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer (Zacks)
May-14-25 06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
May-09-25 12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
12:00PM	Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy? (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
May-08-25 09:55AM	Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect? (Zacks) +5.22%
09:40AM	Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? (Zacks)
May-02-25 09:29AM	Q1 2025 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents) +33.70%
03:18AM	Adaptive Biotechnologies Corp (ADPT) Q1 2025 Earnings Call Highlights: Strong MRD Revenue ... (GuruFocus.com)
May-01-25 09:46PM	Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:00PM	Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Adaptive Biotechnologies: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-24-25 09:45AM	Aristotle Focus Growth Q1 2025 Commentary (Seeking Alpha) +6.91%
Apr-14-25 02:09PM	Aristotle Large Cap Growth Q1 2025 Commentary (Seeking Alpha)
Apr-12-25 09:15AM	OpenAI And Andreessen Horowitz Lead $43M Round For Cybersecurity Startup Taking On AI Scammers, Deepfakes, And Voice Spoofs (Benzinga)
Apr-10-25 04:05PM	Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 (GlobeNewswire) -7.82%
Apr-08-25 08:00AM	Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Surveillance in Mantle Cell Lymphoma (GlobeNewswire)
Mar-20-25 03:06PM	Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March (InsiderMonkey)
Mar-11-25 08:00AM	Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma (GlobeNewswire) +12.29%
Feb-14-25 10:44AM	Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank (TipRanks)
Feb-12-25 12:00PM	Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
09:56AM	Q4 2024 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents)
09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
02:11AM	Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Call Highlights: Strong MRD Revenue ... (GuruFocus.com)
Feb-11-25 06:30PM	Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:45PM	Adaptive Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-10-25 07:19AM	Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-05-25 04:05PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire) +9.23%
Feb-04-25 10:28AM	PhaseV and Alimentiv to support execution of adaptive clinical trials for GI (Clinical Trials Arena)
Jan-23-25 05:06PM	Why Adaptive Biotechnologies Corporation (ADPT) Is Skyrocketing Now (Insider Monkey)
06:21AM	Why Is Andreas Halvorsen Bullish On Adaptive Biotechnologies Corporation (ADPT) Now? (Insider Monkey)
Jan-22-25 04:05PM	Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 (GlobeNewswire) +7.52%
Jan-17-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-16-25 08:33AM	Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock? (Zacks)
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire) +17.96%
Jan-14-25 07:30AM	Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients (GlobeNewswire) -6.04%
Jan-07-25 07:30AM	Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025 (GlobeNewswire)
Jan-02-25 04:05PM	Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +16.32%
Dec-09-24 09:53AM	Adaptive unveils data of MRD assessment test in blood cancer treatment (Medical Device Network)
Dec-07-24 06:30PM	Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ and Its Impact on Blood Cancer Treatment Decisions (GlobeNewswire)
Dec-05-24 07:16AM	Adaptive Research and WRO to expand cancer trial access in San Francisco Bay Area (Clinical Trials Arena)
Dec-03-24 07:30AM	Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting (GlobeNewswire)
Nov-29-24 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-25-24 01:55PM	Novotech report notes shift to adaptive designs in clinical trials (Clinical Trials Arena) +18.98%
Nov-15-24 09:55AM	Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know (Zacks) -8.96%
Nov-08-24 10:18AM	Q3 2024 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents)
02:29AM	Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highlights: Strong MRD Growth Amidst ... (GuruFocus.com)
Nov-07-24 06:30PM	Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:15PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
05:11PM	Adaptive Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Assessing Measurable Residual Disease in Mantle Cell Lymphoma (GlobeNewswire)
Nov-06-24 07:28AM	Earnings To Watch: Adaptive Biotechnologies Corp (ADPT) Reports Q3 2024 Result (GuruFocus.com)
Oct-09-24 04:05PM	Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PISKEL KYLE	Chief Financial Officer	May 16 '25	Sale	8.89	1,929	17,149	277,396	May 19 07:59 PM
ROBINS HARLAN S	Chief Scientific Officer	May 01 '25	Option Exercise	6.32	68,412	432,364	1,347,936	May 05 05:27 PM
ROBINS HARLAN S	Chief Scientific Officer	May 01 '25	Sale	7.35	68,412	502,828	1,279,524	May 05 05:27 PM
Harlan Robins	Officer	May 01 '25	Proposed Sale	7.36	68,412	503,512		May 01 05:38 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 24 '25	Option Exercise	6.32	1,698	10,731	1,281,222	Mar 26 06:48 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 24 '25	Sale	9.00	1,698	15,282	1,279,524	Mar 26 06:48 PM
Harlan Robins	Officer	Mar 24 '25	Proposed Sale	8.66	1,698	14,705		Mar 24 05:45 PM
PISKEL KYLE	Chief Financial Officer	Mar 14 '25	Option Exercise	6.32	2,500	15,800	271,510	Mar 17 07:34 PM
GRIFFIN MICHELLE RENEE	Director	Mar 13 '25	Sale	7.19	36,291	260,932	15,394	Mar 17 07:33 PM
GRIFFIN MICHELLE RENEE	Director	Mar 13 '25	Proposed Sale	7.19	36,291	260,861		Mar 13 05:28 PM
HERSHBERG ROBERT	Director	Mar 12 '25	Sale	7.59	53,000	402,270	69,690	Mar 12 07:48 PM
NEUPERT PETER M	Director	Mar 10 '25	Option Exercise	4.07	50,000	203,500	234,690	Mar 12 07:47 PM
NEUPERT PETER M	Director	Mar 10 '25	Sale	7.05	10,000	70,500	224,690	Mar 12 07:47 PM
HERSHBERG ROBERT	Director	Mar 12 '25	Proposed Sale	7.59	53,000	402,270		Mar 12 05:30 PM
NEUPERT PETER M	Director	Mar 10 '25	Proposed Sale	7.05	10,000	70,450		Mar 10 02:48 PM
LO FRANCIS	Chief People Officer	Mar 05 '25	Sale	6.99	20,875	145,845	332,846	Mar 06 07:22 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Mar 05 '25	Sale	6.98	26,023	181,641	347,238	Mar 06 07:22 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Mar 05 '25	Sale	6.98	44,665	311,792	392,723	Mar 06 07:21 PM
PISKEL KYLE	Chief Financial Officer	Mar 05 '25	Sale	6.98	10,320	72,072	269,010	Mar 06 07:20 PM
RUBINSTEIN JULIE	President and COO	Mar 05 '25	Sale	6.98	59,505	415,540	588,249	Mar 06 07:19 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 05 '25	Sale	6.99	96,656	675,219	1,279,524	Mar 06 07:18 PM
ROBINS CHAD M	CEO and Chairman	Mar 05 '25	Sale	6.98	117,351	819,471	2,814,350	Mar 06 07:17 PM
ROBINS CHAD M	CEO and Chairman	Mar 06 '25	Sale	7.64	102,218	780,946	2,959,249	Mar 06 07:17 PM
GRIFFIN MICHELLE RENEE	Director	Mar 06 '25	Sale	7.94	15,664	124,372	51,685	Mar 06 07:14 PM
MICHELLE GRIFFIN	Director	Mar 06 '25	Proposed Sale	7.94	15,664	124,440		Mar 06 04:10 PM
ROBINS CHAD M	CEO and Chairman	Feb 19 '25	Option Exercise	6.32	186,080	1,176,026	2,762,781	Feb 21 07:28 PM
ROBINS CHAD M	CEO and Chairman	Feb 20 '25	Option Exercise	6.32	99,107	626,356	2,675,808	Feb 21 07:28 PM
ROBINS CHAD M	CEO and Chairman	Feb 19 '25	Sale	8.46	186,080	1,574,237	2,576,701	Feb 21 07:28 PM
ROBINS CHAD M	CEO and Chairman	Feb 20 '25	Sale	8.44	99,107	836,463	2,576,701	Feb 21 07:28 PM
Chad Robins	Officer	Feb 20 '25	Proposed Sale	8.37	99,107	829,526		Feb 20 04:02 PM
Chad Robins	Officer	Feb 19 '25	Proposed Sale	8.37	186,080	1,557,490		Feb 19 04:51 PM
ROBINS CHAD M	CEO and Chairman	Feb 18 '25	Option Exercise	6.32	211,160	1,334,531	2,787,861	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 14 '25	Option Exercise	6.32	158,921	1,004,381	2,735,622	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 13 '25	Option Exercise	6.32	100,287	633,814	2,676,988	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 18 '25	Sale	8.50	211,160	1,794,860	2,576,701	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 14 '25	Sale	8.46	158,921	1,344,472	2,576,701	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 13 '25	Sale	8.44	100,287	846,422	2,576,701	Feb 18 08:21 PM
Chad Robins	Officer	Feb 18 '25	Proposed Sale	8.27	211,160	1,746,293		Feb 18 05:35 PM
Chad Robins	Officer	Feb 14 '25	Proposed Sale	8.33	158,921	1,323,812		Feb 14 04:11 PM
Chad Robins	Officer	Feb 13 '25	Proposed Sale	8.52	100,287	854,445		Feb 13 05:11 PM
PISKEL KYLE	Chief Financial Officer	Nov 18 '24	Sale	4.98	248	1,235	154,330	Nov 19 06:45 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Oct 08 '24	Option Exercise	1.98	5,000	9,900	253,290	Oct 10 05:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADPT

Adaptive Biotechnologies Corp

Upgrade your FINVIZ experience